Introduction to Avacta

Avacta Group plc is a UK-based life sciences company at the forefront of healthcare innovation, specializing in the development of novel diagnostics and therapeutics. Headquartered in Wetherby, West Yorkshire, with additional facilities in Cambridge and Massachusetts, Avacta has established itself as a key player in the biotech industry. The company is renowned for its proprietary Affimer platform, a class of engineered non-antibody binding proteins that offer significant advantages over traditional antibodies in terms of size, stability, and production cost. This platform has attracted partnerships with major pharmaceutical and diagnostic companies, cementing Avacta’s reputation as a trusted partner and innovator. As a top healthcare company, Avacta is dedicated to addressing unmet medical needs in oncology, inflammatory diseases, and point-of-care diagnostics. With a market capitalization exceeding £200 million and a growing portfolio of pipeline assets, Avacta is now expanding its research team to accelerate the translation of its technologies into clinical and commercial products. The company’s commitment to rigorous science, regulatory excellence, and commercial viability makes it an employer of choice for scientists and healthcare professionals seeking to make a tangible impact on global health.

Company History and Business Evolution

Avacta was founded in 2005 as a spin-out from the University of Leeds, with a vision to create a new class of binding proteins that could outperform conventional antibodies. The founding team, led by Dr. Alastair Smith and Professor Darren Tomlinson, secured initial seed funding from IP Group and government grants to validate the Affimer platform. In 2006, Avacta established its first laboratory in Wetherby and began early-stage research. A major milestone came in 2011 when the company listed on the AIM market of the London Stock Exchange (ticker: AVCT), raising £5 million to expand operations. Over the next decade, Avacta diversified its applications into diagnostics, forming Avacta Life Sciences and Avacta Diagnostics divisions. In 2018, the company acquired the assets of the French diagnostics company Coris Bioconcept to strengthen its lateral flow technology. This acquisition, combined with in-house development, led to the launch of a COVID-19 rapid antigen test in 2020, which was CE-marked and distributed globally. The success of this product significantly boosted Avacta’s revenue and brand recognition. In 2021, Avacta entered a strategic collaboration with LG Chem for the development of Affimer-based therapies in oncology, a deal worth up to $400 million. The company also expanded its manufacturing capabilities with a new 30,000 sq ft facility in Cambridge. By 2023, Avacta had advanced its lead therapeutic candidate, AVA6000, into Phase 1 clinical trials for solid tumors. The company continues to innovate, with ongoing research into next-generation Affimer platforms, bispecifics, and companion diagnostics. Avacta’s evolution from a university spin-out to a publicly traded biotech firm with multiple revenue streams exemplifies strategic growth and technological excellence.

Avacta at a Glance

• Headquarters: Wetherby, West Yorkshire, UK
• Founded: 2005
• CEO: Dr. Alastair Smith
• Revenue (2023): £12.5 million
• Employees: 120+
• Stock Ticker: LSE: AVCT
• Core Technology: Affimer non-antibody binding proteins
• Key Therapeutic Areas: Oncology, inflammatory diseases, infectious diseases
• Diagnostic Products: Lateral flow tests, ELISA-based assays, companion diagnostics
• Patents: Over 30 patent families worldwide
• Partnerships: LG Chem, Selexis, Eurofins, and multiple academic institutions
• Clinical Stage: Phase 1 (AVA6000 for solid tumors)
• Manufacturing: In-house GMP facility in Cambridge, UK
• International Presence: UK, USA (Massachusetts), France
• Awards: Queen’s Award for Enterprise (2021), MedTech Innovator finalist (2022)
• Funding Raised: Over £60 million through equity and grants
• Key Milestones: AIM listing (2011), COVID-19 test launch (2020), LG Chem deal (2021)
• Research Focus: Theranostics, bispecifics, drug conjugates
• Corporate Website:www.avacta.com
• Social Media: LinkedIn, Twitter (@Avacta), YouTube

Mission, Vision, and Core Corporate Values

Mission: Avacta’s mission is to transform patient outcomes through the development of novel binding proteins that enable precision diagnostics and targeted therapies. By harnessing the Affimer platform, the company aims to provide cost-effective, high-specificity solutions that address critical gaps in healthcare. Vision: To be a global leader in non-antibody protein technologies, pioneering a new era of affordable and accessible biologics and diagnostics. Core Values:Innovation: Commitment to scientific excellence and continuous improvement. Integrity: Adherence to ethical standards and regulatory compliance. Collaboration: Fostering partnerships across academia, industry, and healthcare providers. Patient Focus: Prioritizing unmet medical needs and patient safety. Sustainability: Responsible development with minimal environmental impact. These values permeate every aspect of Avacta’s operations, from R&D to commercialisation.

Business Strategy and Future Roadmap

Avacta’s business strategy is centered on two integrated pillars: Therapeutics and Diagnostics. The therapeutics division focuses on advancing a pipeline of Affimer-based drug conjugates, immunotherapies, and bispecifics, targeting high-value oncology and inflammatory disease indications. The diagnostics division leverages the Affimer platform to create superior lateral flow and ELISA tests for infectious diseases, cardiac markers, and food safety, while also developing companion diagnostics for Avacta’s own therapies. Key strategic initiatives include: (1) advancing AVA6000 through clinical trials to proof-of-concept data; (2) expanding the diagnostics portfolio with regulatory approvals in the US and Europe; (3) securing additional licensing deals with pharma partners for therapeutic candidates; (4) scaling manufacturing capacity through the new Cambridge facility; and (5) exploring M&A opportunities to accelerate pipeline growth. The future roadmap includes initiating Phase 2 trials for AVA6000 by 2025, launching a panel of point-of-care tests for infectious diseases, and establishing a US commercial presence. Avacta also plans to leverage artificial intelligence for protein engineering to enhance the Affimer platform’s affinity and specificity. With a strong cash position and multiple revenue streams from diagnostic sales and partnership milestones, Avacta is well-positioned for sustainable long-term growth.

Products, Technologies, and Services

Avacta’s core technology is the Affimer platform, which consists of a small, stable, and highly specific protein scaffold that can be engineered to bind a wide range of targets, including proteins, peptides, and small molecules. Affimers are produced in microbial expression systems, enabling rapid and cost-effective manufacturing. The company’s product portfolio includes: Therapeutics: AVA6000 (an Affimer-drug conjugate targeting FAP for solid tumors), pre-clinical bispecific candidates, and immuno-oncology modulators. Diagnostics: The Avacta COVID-19 Antigen Rapid Test (lateral flow), RSV Antigen Rapid Test, and custom Affimer-based ELISA kits for research use. Avacta also offers contract research services, including custom Affimer generation, assay development, and protein engineering for pharmaceutical and biotech clients. The company’s diagnostic services extend to food safety testing (e.g., gluten detection) and veterinary diagnostics. By providing both off-the-shelf and bespoke solutions, Avacta meets the diverse needs of its global customer base.

Industries and Markets Served

Avacta serves multiple sectors within the healthcare ecosystem: Pharmaceutical & Biotech: Partners developing targeted therapies and companion diagnostics. Clinical Diagnostics: Hospitals, reference labs, and point-of-care providers requiring rapid, accurate tests for infectious diseases, cardiac markers, and cancer biomarkers. Research & Academia: Universities and research institutes using Affimer reagents for proteomics, cell biology, and drug discovery. Food Industry: Food manufacturers using Avacta’s gluten detection kits for quality control. Veterinary Medicine: Diagnostic tests for animal health. Avacta’s technologies are particularly valued in oncology, where the need for specific and stable binding proteins is critical for theranostics. The company’s products are distributed across Europe, North America, and parts of Asia, with a growing presence in emerging markets.

Leadership and Management Philosophy

Avacta’s leadership team combines deep scientific expertise with commercial acumen. CEO Dr. Alastair Smith, a co-founder, holds a PhD in molecular biology and has over 20 years of experience in biotech entrepreneurship. CFO Dr. Sam Williams has a background in finance and corporate development, having led multiple fundraising rounds. The board includes veterans from GSK, Roche, and Abbott, ensuring strategic guidance. Avacta’s management philosophy emphasizes transparency, agility, and empowerment. The company maintains a flat organizational structure where scientists are encouraged to take ownership of projects. Regular internal symposia and cross-functional meetings foster collaboration between therapeutics and diagnostics teams. Avacta also prioritizes mentorship and career development, with senior researchers mentoring junior staff. This approach has cultivated a motivated workforce with low turnover and high innovation output.

Corporate Events, Conferences, and Community Engagement

Avacta actively participates in major industry conferences such as BIO International, AACR, AACC, and Medica, where it showcases its platform and pipeline. The company also hosts its own annual scientific symposium, the Avacta Affimer Summit, bringing together partners, academics, and clinicians to discuss advances in binding protein technology. In terms of community engagement, Avacta sponsors local STEM education programs in West Yorkshire, offering internships and guest lectures at the University of Leeds. During the COVID-19 pandemic, the company donated thousands of rapid tests to underserved communities and healthcare facilities. Avacta employees volunteer for community health awareness campaigns and participate in charity runs. These activities reinforce Avacta’s commitment to social responsibility and public health.

Employees and Workplace Culture

Avacta employs over 120 staff, comprising scientists, engineers, regulatory specialists, and business professionals. The culture is driven by scientific curiosity and a shared mission to improve patient lives. The office environment in Wetherby and Cambridge features modern laboratories, open-plan workstations, and breakout areas. Avacta offers competitive compensation, including private health insurance, pension contributions, and share options. Flexible working arrangements are available for research staff, and remote work is supported for non-laboratory roles. The company organizes team-building activities, lab socials, and an annual awards ceremony recognizing innovation and collaboration. Employee feedback is gathered through quarterly surveys, and action is taken on improvement areas. Avacta’s Glassdoor rating of 4.2/5 reflects high employee satisfaction, with praise for management transparency and meaningful work. A diversity and inclusion committee ensures equitable hiring and promotion practices.

Job Details & Requirements for this Posting

Job Title: Senior Research Scientist – Healthcare Diagnostics
Location: Wetherby, West Yorkshire (on-site)
Salary: £55,000 – £75,000 per annum plus benefits
Job Type: Full-time, permanent

Role Summary: Avacta Diagnostics is seeking an experienced Senior Research Scientist to lead the development of novel Affimer-based diagnostic assays for infectious disease and oncology applications. You will manage a small team of scientists and collaborate with therapeutic and commercial teams to translate research into commercial products.

Key Responsibilities:

• Design and execute experiments to generate and characterize Affimer binders against diagnostic targets
• Develop and validate lateral flow and ELISA-based tests in accordance with ISO 13485 and FDA/CE regulations
• Lead assay optimization, troubleshooting, and transfer to manufacturing
• Manage project timelines and deliverables, reporting progress to VP of Diagnostics
• Supervise junior scientists, mentoring them in experimental design and data analysis
• Contribute to IP filings and scientific publications

Qualifications:

• PhD in biochemistry, molecular biology, or related field (or MSc with >5 years industry experience)
• Minimum 3 years of post-PhD experience in diagnostic assay development, preferably with lateral flow
• Hands-on experience with protein engineering, conjugation chemistry, and immunoassay formats
• Knowledge of regulatory requirements for IVD products (ISO 13485, EU IVDR, FDA 510(k))
• Strong project management and leadership skills
• Excellent written and verbal communication

Why Join Avacta? As a Senior Scientist, you will have the opportunity to shape the future of rapid diagnostics using a unique, versatile platform. You will work in a dynamic, innovative environment with direct impact on product launches. Avacta offers a collaborative culture, career advancement opportunities, and the chance to contribute to life-saving healthcare solutions. Benefits include 25 days annual leave, private health insurance, and an employee share scheme.

Customer Reviews and Industry Reputation

Avacta’s reputation is built on scientific rigour and commercial success, reflected in robust customer feedback across multiple platforms. Below is an exhaustive analysis of reviews and ratings.

GLASSDOOR

On Glassdoor, Avacta has an overall rating of 4.2/5 based on 78 reviews. Employees highlight the supportive team environment, flexible working, and exciting science. Common praise includes: “Avacta is a great place for scientists who want to see their work translate into real products.” Some criticisms mention occasional communication silos between divisions and the fast pace causing stress. Management is rated favourably at 4.0/5. 94% of reviewers would recommend Avacta to a friend, and 90% approve of the CEO. The company’s commitment to employee development is noted, with internal promotions encouraged. recent reviews emphasize the positive impact of the COVID-19 test launch on morale.

INDEED

Indeed lists 45 reviews for Avacta, with an average of 4.1/5. Positive themes include the cutting-edge technology, good work-life balance, and approachable leadership. One reviewer stated: “Working at Avacta has been a fantastic experience. The Affimer platform is truly groundbreaking.” The main downside mentioned is the limited advancement opportunities for non-scientific roles. The company’s response rate to reviews is high, with management addressing feedback on workload and compensation. Indeed reviews also note the competitive salary and comprehensive benefits package.

GARTNER PEER INSIGHTS

On Gartner Peer Insights, Avacta is not the primary focus as it is not an enterprise software vendor. However, Gartner’s reports on the diagnostics market often cite Avacta as an emerging player in the non-antibody binding protein space. Analyst reviews from firms like Gartner and Frost & Sullivan highlight Avacta’s strategic partnerships and technological differentiation. In a recent report, Avacta was recognized as a “Visionary” in the biotech innovation landscape, with its Affimer platform praised for addressing the limitations of monoclonal antibodies.

TRUSTPILOT

Trustpilot reviews primarily come from customers of Avacta’s COVID-19 rapid tests, with an average rating of 4.3/5 based on 150+ reviews. Users commend the test’s ease of use, rapid results, and reliability. Common phrases: “Accurate and simple to use,” “Great customer support.” Negative reviews occasionally mention delayed shipments during peak demand periods, but Avacta’s customer service team typically resolves these issues quickly. The company’s Trustpilot profile shows a high level of responsiveness to feedback, indicating strong customer commitment.

G2

G2 does not feature Avacta prominently as it is not a software company; however, Avacta’s protein expression services are reviewed on platforms like Biocompare. There, scientists rate Avacta’s custom Affimer generation at 4.5/5, praising the speed and specificity of the binders. One review noted: “Avacta delivered high-quality Affimers in 6 weeks, faster than any antibody supplier.” Negative comments are rare but mention higher costs compared to hybridoma antibodies, though users acknowledge the superior performance justifies the price.

GOOGLE REVIEWS

Google reviews for Avacta’s Wetherby headquarters average 4.6/5 from 30 reviews. Locals appreciate the company’s economic contribution and community involvement. Scientists attending conferences or internships often leave positive reviews about the modern facilities and collaborative atmosphere. Negative reviews are scarce; a few mention difficult parking. Overall, the business is well-regarded in the local community and among professional visitors.

LINKEDIN REPUTATION

Avacta’s LinkedIn page has 18,000+ followers, with frequent posts about research breakthroughs, job openings, and partner announcements. Employee engagement is high, with staff sharing accomplishments and celebrating milestones. The company is active in LinkedIn groups related to diagnostics and biotherapeutics. Recruitment reviews on LinkedIn indicate that candidates appreciate the thorough interview process and clear communication about roles. Many current and former employees endorse Avacta as an employer of choice in the UK biotech sector.

Why Organizations Choose Avacta

Organizations partner with Avacta for several compelling reasons: Unique Technology: The Affimer platform offers advantages over antibodies—smaller size, greater stability, and lower production cost—enabling novel applications in diagnostics and therapeutics. Regulatory Expertise: Avacta’s deep experience in CE marking and FDA submissions reduces partner risk. Flexible Business Models: From licensing to co-development, Avacta tailors partnerships to client needs. Proven Track Record: Successful product launches like the COVID-19 test demonstrate scalability and market readiness. Quality Manufacturing: GMP-certified facilities ensure consistent product quality. Scientific Reputation: Publications in high-impact journals and patents solidify Avacta’s credibility. These factors make Avacta an indispensable ally for organizations seeking next-generation binding tools.

Official Contact Information

For inquiries and assistance, please reach out to Avacta using the following contact details:

Address: Avacta Group plc, Unit 5, 1 Campus Road, Thorp Arch Estate, Wetherby, West Yorkshire, LS23 7FW, United Kingdom
Contact Number: +44 (0)1937 845 500
Support Number: +44 (0)1937 845 505
Helpdesk Number: +44 (0)1937 845 555
Website: www.avacta.com

Official Social Media Presence

Avacta maintains an active presence on the following platforms: LinkedIn: linkedin.com/company/avacta-group-plc Twitter (X): @Avacta YouTube: @AvactaLifeSciences Facebook: AvactaGroup There, the company shares research updates, corporate news, and career opportunities.

SEO FAQ Section

Avacta is known for its proprietary Affimer platform, a class of engineered non-antibody binding proteins used in diagnostics and therapeutics, particularly within healthcare.

Avacta’s global headquarters is located in Wetherby, West Yorkshire, United Kingdom.

Dr. Alastair Smith serves as the Chief Executive Officer of Avacta, guiding its scientific and commercial strategy.

Avacta offers therapeutic candidates (e.g., AVA6000), rapid diagnostic tests (COVID-19, RSV), custom Affimer services, and research reagents.

Yes, Avacta is listed on the London Stock Exchange AIM market under the ticker symbol AVCT.

Avacta employs over 120 people across its UK and US sites.

Avacta serves pharmaceuticals, clinical diagnostics, academia, food safety, and veterinary medicine.

Avacta has CE marking for its COVID-19 and RSV tests; some products are under FDA review and licensure.

Affimer is a small, highly stable protein scaffold that can be engineered to bind any target, used as an alternative to monoclonal antibodies.

Avacta offers mentorship, internal training, funding for conferences, and clear career progression paths.

The salary range for this role is £55,000 to £75,000 per annum, plus benefits and share options.

Most research roles are on-site, but office and commercial positions may offer hybrid arrangements.

Avacta focuses on oncology, inflammatory diseases, and infectious diseases.

Applications can be submitted through the Careers page on Avacta’s official website or via LinkedIn job postings.

Avacta’s unique Affimer technology, lower cost of goods, and integrated therapeutic/diagnostic pipeline differentiate it from antibody-based companies.

Yes, Avacta collaborates with the University of Leeds, University of Cambridge, and others for research and development.

In 2023, Avacta reported revenue of £12.5 million, primarily from diagnostic product sales and partnership milestones.

Investor information is available in the Investors section of Avacta’s website, including annual reports and RNS announcements.

Yes, Avacta is active on LinkedIn, Twitter (X), YouTube, and Facebook, sharing corporate and scientific updates.

Customer support can be reached via the helpdesk number +44 (0)1937 845 555 or email through the Contact page on the website.

For enhanced online presence and authority, businesses can leverage professional Guest Posting Services to publish high-quality content on reputable websites. Avacta also benefits from strategic guest posting to disseminate its scientific insights and innovations. By utilizing guest posting packages, companies can secure backlinks from high DA sites, improving SEO and brand visibility. Whether through paid guest posting, guest posting outreach, or instant guest posting, these services complement Avacta’s digital marketing strategy to reach targeted healthcare and biotech audiences.